Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

d_risk Apr. 2 at 7:14 PM

$PHAR - Pharming Group N.V. ADS each representing 10 - 20F - Updated Risk Factors PHAR flags intensifying RUCONEST/Joenja competition from new 2025 prophylactic and acute HAE therapies (including oral and gene therapy candidates), rising global pricing/reimbursement pressure driven by MFN-style U.S. models and state cost controls, heightened trade/tariff and geopolitical risks to supply and sales, and new U.S. insider reporting rules, while prior ESG and internal-control material-weakness risks are dropped from the section. #Biopharmaceuticals #RareDiseaseTherapies #PricingPressure #GeopoliticalRisk #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/PHAR/20-F/2026-04-02

0 · Reply

OwlKing Mar. 26 at 12:30 AM

$PHAR

0 · Reply

OwlKing Mar. 26 at 12:29 AM

$PHAR Real revenue + growth

0 · Reply

SuperGreenToday Mar. 24 at 2:21 PM

$PHAR

0 · Reply

nick2341 Mar. 24 at 6:16 AM

$PHAR japan

2 · Reply

nick2341 Mar. 24 at 6:14 AM

$PHAR approved!

0 · Reply

BGG13 Mar. 23 at 3:55 PM

$PHAR EMA CHMP agenda: 3.1.4. Leniolisib - Orphan - EMEA/H/C/005927 Pharming Technologies B.V.; treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) Scope: Opinion Action: For adoption List of Outstanding Issues adopted on 30.05.2024, 25.01.2024, 09.11.2023, 20.07.2023. List of Questions adopted on 24.01.2023.

0 · Reply

ZacksResearch Mar. 3 at 1:41 PM

$PHAR heading into Q4 — make-or-break moment? 👀 All eyes are on Ruconest and Joenja sales as Pharming Group gears up to report, with pipeline updates and clarity around key regulatory setbacks front and center. This isn’t just another quarter — it’s about confidence going forward. Will management steady the ship or raise new questions? Full breakdown before earnings 👉 https://www.zacks.com/stock/news/2877894/pharming-group-gears-up-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2877894-teaser-35821&ADID=SYND_STOCKTWITS_TWEET_2_2877894_TEASER_35821

0 · Reply

ZacksResearch Mar. 3 at 12:41 PM

$PHAR's Q4 earnings: Can Ruconest drive growth amidst challenges? 🤔 💊 Focus on Ruconest sales, expected to have boosted Q4 figures, despite the withdrawal from non-U.S. markets 🌍 Joenja sales expected to grow, driven by an increase in U.S. and U.K. patients on paid therapy 🔍 Investors await updates on pipeline setbacks and regulatory hurdles Full analysis here 👉 https://www.zacks.com/stock/news/2877894/pharming-group-gears-up-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2877894-body-35822&ADID=SYND_STOCKTWITS_TWEET_2_2877894_BODY_35822

0 · Reply

OfficialStocktwitsUser Mar. 2 at 8:02 PM

$PHAR RSI: 44.86, MACD: -0.4008 Vol: 0.52, MA20: 16.35, MA50: 17.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Mar 27, 2026, 2:00 AM EDT - 9 days ago

Market Cap	1.17B
Revenue (ttm)	376.13M
Net Income (ttm)	2.85M
EPS (ttm)	N/A
PE Ratio	1,692.00
Forward PE	45.12
Profit Margin	0.76%
Debt to Equity Ratio	0.02

Volume	41,500
Avg Vol	29,146
Day's Range	N/A - N/A
Shares Out	70.14M
Stochastic %K	71%
Beta	0.05
Analysts	Sell
Price Target	$39.00